Peptizole

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peptizole

Quick Facts

Property Description
Active Ingredient Omeprazole (a substituted benzimidazole)
Form Oral paste
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Gastric protection via acid suppression
Origin Synthetic compound

What Type of Medicine is Peptizole?

Peptizole is a veterinary medicinal preparation primarily defined by its active component, Omeprazole, and its classification as an antisecretory compound. This medication belongs to the Proton Pump Inhibitor (PPI) pharmacological class, meaning its essential function is to control the volume of acid produced in the stomach. The action of Omeprazole as an irreversible inhibitor of H^+K^+-ATPase (the gastric acid pump) serves to regulate this process. The compound Omeprazole is a synthetic substance and a representative of the substituted benzimidazoles, a chemical group known for its selective action in controlling gastric acidity.


Peptizole Composition and Formulation

The formulation of Peptizole is an oral paste, a single-ingredient product where the active component, Omeprazole, is suspended in an inert, palatable base. The use of the oral paste as the unique dosage form facilitates accurate and direct oral administration specifically for horses, including foals and breeding stallions, marking a key differentiation from standard human capsule forms. The composition remains focused, containing only the Omeprazole as the therapeutic agent, ensuring its function is directed toward acid inhibition. The efficacy of the compound's structure enables profound acid reduction.


What is the General Purpose of Omeprazole in Peptizole?

The general purpose of Omeprazole in Peptizole is to provide profound gastric protection by significantly reducing the stomach's total acid output. By blocking the acid pumps, the medication creates a much less corrosive environment within the stomach and the upper gastrointestinal tract. A typical use scenario involves administering the paste to manage situations where high acid levels cause irritation. This generalized acid suppression offers a substantial benefit by relieving the irritation and discomfort that arise from excessive acidity and supporting the overall health of the gastric lining.

Regulatory References

  1. FDA: Omeprazole for Horses

What side effects are possible with Peptizole?

Possible Side Effects and Safety Information

This information details the officially documented adverse reactions and safety constraints for Peptizole, as reported in governmental regulatory documents. Adverse reactions are classified by how often they occur and which body system they affect (System Organ Class).


Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Very Common (≥ 1/10) Headache, Diarrhea
Common (≥ 1/100 to < 1/10) Nausea, Abdominal Pain, Vomiting, Fatigue
Uncommon (≥ 1/1,000 to < 1/100) Rash, Pruritus, Dizziness
Rare (≥ 1/10,000 to < 1/1,000) Thrombocytopenia, Angioedema

Serious adverse reactions, though rare, are critical events documented in regulatory sources. These include Angioedema, Agranulocytosis (a severe decrease in white blood cells), Hepatic Failure, and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome.


Safety Constraints and Considerations

Population-Specific Safety: The drug is not recommended for use in severe hepatic impairment. Safety and efficacy have not been established in children under 12 years of age. Use during pregnancy is advised only if the potential benefit outweighs the potential risk to the fetus.

Exposure-Related Patterns: Some gastrointestinal effects are often transient and more common during the first week of treatment. The risk of osteoporotic fractures is reported to increase with duration of therapy of one year or longer.

Restrictions: Peptizole is contraindicated in patients with a known hypersensitivity to the active substance. Prolonged use (typically over 3 months) may cause hypomagnesemia (low magnesium levels). The official label advises that liver enzymes should be monitored periodically in patients with moderate hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of the active ingredient in Peptizole by detailing the clinical manifestations and the required emergency response actions.

Documented Manifestations

Overdosage is formally documented to present with several transient symptoms. These include gastrointestinal effects such as nausea, vomiting, abdominal pain, and diarrhea. Central nervous system (CNS) effects are also noted, including headache, confusion, drowsiness, and blurred vision. Less common autonomic signs such as flushing, dry mouth, increased sweating (diaphoresis), and tachycardia (elevated heart rate) have been reported. Increased drug exposure may be a consideration in patients with pre-existing severe hepatic impairment.

Emergency Response and Management

Acute overdose symptoms are typically classified as transient, and regulatory bodies note that no serious clinical outcome has been reported following acute, high-dose ingestion. In all suspected cases, regulatory guidance explicitly requires that individuals or caregivers seek emergency medical attention right away or contact a Poison Control Center immediately. For veterinary exposures, contacting a Veterinarian or an Animal Poison Control Center is the mandated action. Treatment must be symptomatic and supportive, as no specific antidote is known for this compound. Omeprazole is also extensively protein bound, meaning it is not readily dialyzable.

Therapeutic Uses of Peptizole

Quick Facts on Peptizole Use

  • Gastroesophageal Reflux Disease (GERD): May offer symptomatic support for acid reflux and heartburn.
  • Erosive Esophagitis: Helps facilitate the healing of acid-related damage to the esophagus.
  • Ulcer Management: Utilized in the management of duodenal and gastric ulcers.
  • Infection Support: Employed alongside appropriate antibiotics for treating ulcers linked to H. pylori bacteria.
  • Hypersecretory Conditions: May address conditions characterized by the stomach producing excessive acid, such as Zollinger-Ellison syndrome.

What Peptizole Treats: Main Uses and Benefits

Peptizole is an established therapeutic option used to address medical conditions associated with high levels of stomach acid. Its primary applications focus on offering symptomatic support and contributing to the healing process of affected tissues.

The medication is used to manage the discomfort associated with Gastroesophageal Reflux Disease (GERD), where the backward flow of stomach acid causes heartburn. It may also be prescribed to facilitate the healing of erosive esophagitis, a condition involving acid-mediated damage to the lining of the esophagus.

Furthermore, Peptizole is utilized in the management of ulcers found in the stomach (gastric ulcers) and the small intestine (duodenal ulcers). In specific therapeutic regimens, it is commonly employed in combination with antibiotic agents to help treat and manage the recurrence of ulcers caused by the Helicobacter pylori (H. pylori) bacteria.

The medication is also a resource for managing pathological hypersecretory conditions, which are rare disorders that result in the stomach producing excessive amounts of acid, such as Zollinger-Ellison syndrome.

Eligibility and Restrictions for Use

Who Can and Cannot Use Peptizole?

The eligibility for Peptizole (Omeprazole oral paste) is strictly defined by its veterinary regulatory label, which specifies the target species and outlines mandatory restrictions based on age, weight, and physiological status.


Official Eligibility Status

Classification Population or Condition
Allowed Horses; Foals 4 weeks of age and older and weighing over 70 kg.
Contraindicated Animals with a known hypersensitivity to Omeprazole or any component of the paste.
Not Recommended Foals under 4 weeks of age or weighing less than 70 kg.
Not Recommended Pregnant or lactating mares (safety has not been assessed).

Eligibility-Related Restrictions

Peptizole is only authorized for use in horses and must not be administered outside of this target species. Use is formally not recommended in pregnant and lactating mares due to insufficient data from regulatory safety assessments. Furthermore, the medicine is not authorised for use in mares producing milk designated for human consumption, a restriction related to established withdrawal period policies. The official label requires a minimum age of four weeks and a minimum weight of 70 kg for use in foals.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Peptizole can affect and be affected by other medications through two primary mechanisms: its effect on gastric pH and its involvement with certain Cytochrome P450 (CYP) enzymes in the liver.

  • Impact on Absorption: By strongly reducing stomach acid, Peptizole can alter the dissolution and absorption of products that require an acidic pH for their bioavailability. This includes certain antifungals, such as ketoconazole and itraconazole, and antiretrovirals like atazanavir and nelfinavir. Concomitant use with nelfinavir is generally contraindicated, and use with atazanavir is typically not recommended, unless specific dosing and timing adjustments are implemented.

  • Enzyme Metabolism: Peptizole is metabolized primarily by the CYP2C19 enzyme and is also a modest inhibitor of this enzyme. This can lead to increased systemic levels of co-administered drugs that are substrates of CYP2C19, such as diazepam, phenytoin, and cilostazol, potentially requiring dose monitoring. Of particular concern is the interaction with the antiplatelet medicine clopidogrel, where Peptizole's inhibition of CYP2C19 can reduce the conversion of clopidogrel to its active metabolite, potentially diminishing its therapeutic effect. Co-administration of these two medicines should generally be discouraged. Enhanced monitoring is also advised for medicines with a narrow therapeutic index, including warfarin, digoxin, methotrexate, and tacrolimus, due to the potential for altered exposure.

Mechanism of Action

Inhibiting the Final Step of Acid Secretion

Peptizole is an inactive prodrug belonging to the class of substituted benzimidazoles. It achieves selective concentration and activation within the highly acidic environment of the secretory canaliculi of the gastric parietal cells. Upon activation, the molecule irreversibly binds to the H^+/ K^+- ATPase enzyme, commonly known as the proton pump. This permanent, covalent modification directly blocks the final common pathway for the secretion of hydrochloric acid into the stomach lumen.


Sustained Modification of Gastric Acid Production

The resulting irreversible enzyme inhibition leads to a dose-dependent reduction of both basal and stimulated gastric acid output. The mechanism requires binding to actively secreted pumps, leading to cumulative inhibition as the drug is administered over time. This targeted molecular modification alters the homeostatic regulation of gastric acid production, and the block in H^+/ K^+- ATPase activity lowers the concentration of hydrochloric acid within the gastric lumen.

Dosage and Administration Information

Instruction Map: How to use Peptizole — Administration Guidelines

This map details the instructions for using Peptizole Oral Paste (Omeprazole), focusing on administration and dosage procedure.


Administration Scope

Category Instruction Entity
Route of administration The medicine is strictly for oral administration, delivered using a calibrated syringe.
Dosing schedule Treatment: The required dose is 4 mg of Omeprazole per kilogram of body weight (BW). Prevention: Dosing is typically 1 mg/kg BW or 2 mg/kg BW, reflecting standard guidelines.
Timing in relation to meals Administration must occur when the animal’s mouth is empty of feed.
Preparation requirements The animal’s body weight must be determined accurately to correctly set the dose on the calibrated syringe.
Age-group administration rules The medicine is approved for use in foals 4 weeks of age and older, with dosing based on the standard mg/kg rule.
Missed-dose rules If any part of the dose is lost during administration, re-dosing is recommended to ensure the full quantity is received.
Special procedural conditions The paste must be deposited onto the back of the tongue or deep into the cheek pouch, and consumption must be ensured.

Instruction Classifications (High-Level)

Category Classification
Administration method type Oral administration (Paste)
Frequency pattern Once daily
Use-context constraints Requires accurate body weight measurement and an empty mouth.

Resulting Procedural Structure

Step sequence:

  • Accurately determine the animal's body weight and set the syringe plunger to the corresponding marking.
  • Ensure the horse's mouth is empty of feed.
  • Deposit the entire dose of the paste onto the back of the tongue or deep into the cheek pouch.
  • Ensure the horse consumes the complete dose; re-dose if the paste is lost.
  • Administer once daily for a minimum of 28 days for treatment, followed by a maintenance course.

Connection to the Overall Use Protocol

Established protocols define a standardized, weight-based administration protocol that outlines the drug's use through two distinct, consecutive cycles: a high-dose, initial 28-day treatment phase and a subsequent lower-dose maintenance phase. This structure dictates the required dosage and once-daily frequency, as well as specific constraints on the administration technique, such as the timing in relation to feeding and the required immediate re-dosing of any lost product.

Recent Clinical Evidence

Clinical evidence exploring the use of Peptizole for treating existing gastric ulcers in horses was conducted using designs, primarily Randomized Controlled Trials (RCTs). These short-term trials involved adult performance horses diagnosed with stomach ulcers. Research examined outcomes by measuring whether ulcers had completely resolved or whether severity scores had changed after a defined time interval.

Findings describe patterns observed in the studies related to the resolution of lesions in a proportion of horses, particularly in the upper (squamous) portion of the stomach. However, studies reported that measurements for ulcers located in the lower (glandular) portion was associated with a lower rate of resolution during the study period.

Prevention was evaluated in controlled studies focusing on episodes where symptoms become more noticeable, such as when horses begin intensive training. Studies monitoring these outcomes reported that the incidence of new ulcer formation was observed to be lower in the group receiving the paste compared to the control group. However, findings indicate that when administration is halted, the gastric lesions may show a return of symptoms.

Research Gaps and Limitations

A limitation noted in the research is the variable pattern of resolution for ulcers located in the glandular region. Furthermore, long-term effects are not fully established, as follow-up durations were limited in primary studies. Because most studies focused on adult racehorses, comparative evidence is lacking for other breeds. While research has explored the use of the paste in specialized groups, such as neonatal foals, data for these groups remain insufficient compared to the data available for adult racehorses.

Frequently Asked Questions (FAQ)

Common questions about Peptizole (FAQ)

Q: What is the main reason Peptizole is prescribed by doctors?

A: According to the official product information, Peptizole is indicated for conditions associated with excessive gastric acid production. The primary reason for official use is for the treatment and prevention of gastric ulcers and related erosions in the approved population. The medicine works by significantly reducing the total acid output in the stomach.


Q: How quickly do people typically start to feel the effects of Peptizole?

A: The action of Peptizole is not immediate upon administration. Regulatory information indicates that the drug's effect is achieved through a cumulative process, meaning the acid suppression builds up over time. Therefore, it may take several days of continuous administration to achieve the maximum level of acid control, as the full effect is cumulative.


Q: Can Peptizole cause drowsiness or affect my ability to drive?

A: Official documents do not generally list drowsiness (somnolence) as a common side effect of the medicine. However, safety information does note that Peptizole may be associated with uncommon effects such as dizziness or vertigo. If these effects occur, activities requiring concentration, such as driving or operating machinery, should be approached with caution.


Q: Are there generic versions of Peptizole available?

A: Yes. Peptizole is a brand name for the active ingredient Omeprazole. This compound is widely available as a generic formulation from other manufacturers, sometimes in different forms or strengths depending on the country and regulatory approval.


Q: Are there known food or drink interactions with Peptizole?

A: Official administration instructions specify that the medicine should be given when the mouth is empty of feed to ensure proper absorption. Additionally, Peptizole's strong acid-reducing effect may alter how certain other substances are absorbed by the body, especially those that rely on an acidic pH.


Q: Why do official documents mention that Peptizole should be used for a specific period of time?

A: The duration of use, such as a mathbf28-day initial treatment period, is based on the findings from clinical trials. This specified duration reflects the time period that was established in studies for achieving the documented therapeutic outcome, such as the healing or resolution of gastric ulcers.


Q: Can taking Peptizole affect the results of certain lab tests?

A: Official warnings note that taking Omeprazole may lead to changes in some laboratory values. This includes the potential for lowering serum magnesium levels ( hypomagnesemia) and affecting results of tests measuring liver enzyme levels during treatment.


Q: Are there official warnings about combining Peptizole with aspirin or NSAIDs?

A: Regulatory documents address potential interactions with blood-thinning and antiplatelet agents like clopidogrel. While specific warnings for aspirin and other non-steroidal anti-inflammatory drugs ( NSAIDs) are not universally highlighted in a prohibitive sense across all regulatory texts, potential interactions related to combination use are factors for official consideration and monitoring.


Q: What happens if a dose of Peptizole is missed?

A: Regulatory guidelines state that if a dose is forgotten, it may be administered as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the forgotten dose should be skipped. Instructions emphasize that two doses should not be taken together to make up for a missed one.


Q: Is there any research looking at Peptizole's impact on Vitamin B12 levels?

A: Yes. Official safety warnings state that long-term treatment with Omeprazole may lead to reduced absorption of Vitamin B12 (cyanocobalamin). This effect can potentially contribute to a deficiency, especially in individuals using the drug for prolonged periods.


Q: Can Peptizole be taken with antacids?

A: Official regulatory documents generally state that Omeprazole may be used in combination with antacids. This is because there is typically no significant pharmacological interaction between the two types of medication that would require changes in the administration schedule.


Q: How long does the effect of one dose of Peptizole typically last?

A: The drug is designed to provide profound and sustained acid suppression. Regulatory studies show that the activity of one dose of Omeprazole is generally sustained for more than mathbf24 hours, which aligns with the official once-daily administration schedule.


Q: Do experts recommend taking Peptizole at a specific time of day?

A: The official schedule dictates administration once daily. While the exact time (morning or evening) is not always specified, the drug is generally considered most effective when taken approximately mathbf30 to mathbf60 minutes before a meal to target the maximum number of active acid pumps.


Q: Is Peptizole considered a drug that can cause dependence?

A: No. The active compound Omeprazole is not classified as a controlled substance under regulatory acts. It is therefore not associated with the potential for misuse or the development of drug dependence.


Q: What kind of research has been done on Peptizole in older adults?

A: Clinical studies have examined the use of the active compound in geriatric populations. The official documentation indicates that for approved uses, no overall differences in safety or effectiveness have been identified compared to younger populations, though how the body processes the drug ( pharmacokinetics) may be altered.


Q: If I am taking Peptizole, is it common to still experience symptoms sometimes?

A: Symptom relief is not guaranteed for all individuals, as efficacy can vary. Furthermore, the official label notes that the resolution of certain types of ulcers may show a variable pattern and may not be complete within the standard treatment period.


Q: How is Peptizole different from a standard H2 blocker?

A: Peptizole belongs to the Proton Pump Inhibitor ( PPI) class, which works by irreversibly blocking the final common pathway for acid secretion. H2 blockers reduce acid by a different mechanism, which involves reversibly blocking histamine receptors on the parietal cells.


Q: Can Peptizole be crushed or chewed, according to official instructions?

A: The specific Peptizole oral paste formulation is administered as a whole dose onto the tongue. For other forms of Omeprazole (such as capsules), instructions often specify that they should not be crushed, chewed, or opened. This is typically to prevent the active ingredient from being destroyed by stomach acid before it can take effect.


Q: What are the official recommendations regarding alcohol consumption while using Peptizole?

A: Official regulatory documents generally do not list alcohol as a direct drug-drug interaction with Omeprazole. However, regulatory texts do not provide a specific recommendation regarding the consumption of alcohol, which is an external factor that can irritate the stomach lining.


Q: Is there scientific evidence supporting the use of Peptizole for stress-related stomach issues?

A: Clinical studies are typically focused on established diagnoses, such as ulcers, rather than the underlying cause like stress. The drug's function is to reduce acid, which is the final common factor leading to gastric damage. The evidence supports the use for conditions where acid suppression is required, regardless of the precise etiology.


Q: Can a person take Peptizole if they are also taking antidepressants?

A: Omeprazole may interact with certain medications that are metabolized by the CYP2 C19 enzyme, which includes some common antidepressants (e.g., citalopram or escitalopram). This potential interaction may lead to increased drug levels, and is a factor for clinical consideration.


Q: Are there any documented cases of overdose with Peptizole?

A: Regulatory documents include a section on overdosage, noting that such events are mathbf rare. When an overdose does occur, symptoms are generally limited to mild, transient effects, such as headache, nausea, and drowsiness.


Q: Why do I hear conflicting information about Peptizole's long-term risks online?

A: The official documentation confirms both the existence of established long-term risks (such as fractures and hypomagnesemia) and noted limitations in the follow-up duration of primary studies. These factors may contribute to public uncertainty and the conflicting information sometimes found online.


Q: Is Peptizole a drug that is widely studied?

A: The active compound Omeprazole is one of the most extensively studied drug compounds globally. The regulatory filing for Peptizole is supported by a significant body of evidence, including Randomized Controlled Trials ( RCTs) conducted in the approved species.


Q: Is Peptizole a drug that causes stomach bleeding?

A: While GI side effects like abdominal pain and nausea are common, major GI events such as acute stomach bleeding are not typically listed as common or very common side effects in official safety summaries.


Q: Can Peptizole interact with herbal supplements?

A: Official documentation advises caution regarding the combined use of Omeprazole with substances metabolized by CYP enzymes, as this includes certain herbal supplements (e.g., St. John's Wort). Such combinations are a factor for clinical consideration.


Q: Why is Peptizole sometimes not recommended for people with kidney disease?

A: Regulatory texts indicate that dose adjustment is generally not required for patients with impaired renal function (kidney disease). The most significant restriction noted is for severe liver impairment, however, caution related to underlying conditions is typically noted in official documents.


Q: Is Peptizole described as a cure for the condition it treats?

A: No. The drug is consistently described in official documents as a treatment for the resolution (healing) and prevention of ulcers and related conditions. It is not classified as a cure for the underlying disease.

How should Peptizole be stored and disposed of?

The storage and disposal of Peptizole oral paste must adhere strictly to the conditions mandated by regulatory authorities to ensure product stability and safety.

Storage Requirements

The product must not be stored above 30°C.

The official shelf life for the product as packaged for sale is two years. However, the stability is reduced once the container is opened; the product must be used within 28 days after the first use. The cap must be replaced after use to maintain the product's integrity.

For safety, the product must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. Regulatory guidelines prohibit discarding the medicine via wastewater or household waste.

Users are instructed to consult with a veterinary surgeon or pharmacist for proper disposal methods that help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Peptizole found in:

A-Z Index: